Rapid protection and vaccination against hepatitis A for travellers

BioDrugs

Volumn 17, Issue SUPPL. 1, 2003, Pages 19-21

  Connor, Bradley A ^a,b   Van Herck, Koen ^c   Van Damme, Pierre ^c  

^a New York Center for Travel and Tropical Medicine   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HAVRIX 720; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATYRIX; IMMUNOGLOBULIN; TYPHOID VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY TITER; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EPIDEMIC; HEPATITIS A; HUMAN; IMMUNITY; IMMUNOGENICITY; INFECTION PREVENTION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; TRAVEL; VACCINATION; VIRUS SHEDDING;

EID: 0038413864     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200317001-00005     Document Type: Review

References (28)

1. Centers for Disease Control and Prevention. Health information for international travel, 2001-2002. Atlanta: US Department of Health and Human services, 2001
2. Connor BA. Value of hepatitis A immunization in the last minute traveler and the use of hepatitis A vaccine in outbreak control. In: Travel & epidemics. 3rd European Conference on Travel Medicine; 2002 May 15-18; Florence, Italy: 65
3. Steffen R. Evaluation of the current status of travel health knowledge, attitudes and practices (KAP) among travellers. In: Travel & epidemics: 3rd European Conference on Travel Medicine; 2002 May 15-18; Florence, Italy: 33
4. Irwin DJ, Millership S. Antibody responses to hepatitis A vaccine in healthy adults. Commun Dis Public Health 2001; 4: 139-40
5. Van Damme P, Lievens M, Stoffel M, et al. Rapid seroconversion rates after first dose of an inactivated hepatitis A vaccine (Havrix 1440™): results of a retrospective analysis. In: Travel & Epidemics: 3rd European Conference on Travel Medicine; 2002 May 15-18; Florence, Italy: 210
6. Garin D, Vidor E, Wallon M, et al. Good immunogenicity of GBM strain inactivated hepatitis A vaccine in healthy male adults. Vaccine 1995; 13: 220-4
7. World Health Organisation. Public health control of hepatitis A: memorandum from a WHO meeting. Bull World Health Organ 1995; 73: 15-20
8. Purcell RH, D'Hondt E, Bradbury R, et al. Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees. Vaccine 1992; 10 Suppl. 1: S148-51
9. McMahon BJ, Beller M, Williams J, et al. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch Pediatr Adolesc Med 1996; 150: 733-9
10. Prikazsky V, Olear V, Cernoch A, et al. Interruption of an outbreak of hepatitis A in two villages by vaccination. J Med Virol 1994; 44: 457-9
11. Robertson BH, D'Hondt EH, Spelbring J, et al. Effect of postexposure vaccination in a chimpanzee model of hepatitis A virus infection. J Med Virol 1994; 43: 249-51
12. Sagliocca L, Amoroso P, Stroffolini T, et al. Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial. Lancet 1999; 353: 1136-9
13. Landry P, Tremblay S, Darioli R, et al. Inactivated hepatitis A vaccine booster given ≥24 months after the primary dose. Vaccine 2000; 19: 399-402
14. Iwarson S, Lindh M, Widerström L. Excellent booster response 4-6 y after a single primary dose of an inactivated hepatitis A vaccine. Scand J Infect Dis 2002; 34: 110-1
15. Van Damme P, Mathei C, Thoelen S, et al. Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity. J Med Virol 1994; 44: 435-41
16. Gil A, Gonzalez A, Dal-Re R, et al. Interference assessment of yellow fever vaccine with the immune response to a single-dose inactivated hepatitis A vaccine (1440 EL.U.): a controlled study in adults. Vaccine 1996; 14: 1028-30
17. Van Hoecke C, Lebacq E, Beran J, et al. Concomitant vaccination against hepatitis A and typhoid fever. J Travel Med 1998; 5: 116-20
18. Bock HL, Kruppenbacher JP, Bienzle U, et al. Does the concurrent administration of an inactivated hepatitis A vaccine influence the immune response to other travelers vaccines? J Travel Med 2000; 7: 74-8
19. Thoelen S, Van Damme P, Leentvaar-Kuypers A, et al. The first combined vaccine against hepatitis A and B: an overview. Vaccine 1999; 17: 1657-62
20. Joines RW, Blatter M, Abraham B, et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults. Vaccine 2001; 19: 4710-9
21. Van Damme P, Leroux-Roels G, Law B, et al. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults. J Med Virol 2001; 65: 6-13
22. Van Herck K, Van Damme P, Goilav C, et al. Long-term immunogenicity and safety of an inactivated hepatitis A vaccine. The 10th International Congress on Infectious Disease; 2002 Mar 11-14; Singapore: 183
23. Van Damme P, Van Herck K, Dieussaert I, et al. Antibody persistence and booster response more than 11 years after immunization with inactivated hepatitis A vaccine [abstract]. 3rd World Congress of Pediatric Infectious Diseases; 2002 Nov 19-23; Santiago, Chile: 253
24. Van Herck K, Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol 2001; 63: 1-7
25. Wiens BL, Bohidar NR, Pigeon JG, et al. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. J Med Virol 1996; 49: 235-41
26. Van Herck K, Beutels P, Van Damme P, et al. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J Med Virol 2000; 60: 1-7
27. Bovier PA, Bock J, Loutan L, et al. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J Med Virol 2002; 68: 489-93
28. Van Herck K, Renard D, Molenberghs G, et al. Model based estimates of long term persistence of vaccine induced hepatitis A antibodies. In: Margolis HS, Alter MJ, Liang TJ, et al., editors. Viral hepatitis and liver disease. 10th International Symposium on Viral Hepatitis and Liver Disease. International Medical Press, 2002: 56-9